Market Overview:
The global tuberculosis (TB) treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of TB, rising awareness about TB and its treatment, and government initiatives for controlling TB. The global tuberculosis (TB) treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into isoniazid, rifampin (Rifadin®, Rimactane®), ethambutol (Myambutol®), pyrazinamide. On the basis of application, the market is segmented into active TB and latent TB. The active TB segment accounted for majority share in 2017 owing to high prevalence rate of active tuberculosis across regions.
 Treatment Industry Outlook.svg)
Product Definition:
Tuberculosis (TB) Treatment is the use of antibiotics to cure tuberculosis. It is important because tuberculosis is a serious disease that can be fatal if left untreated.
Isoniazid:
Isoniazid, also known as nitrofuran, is an organic compound and an azide derivative. It has a molecular formula of CNO and a molecular weight of 132.8. The chemical is pale yellow in color with a crystalline melting point of 130-131 °C and boiling point of 381-384 °C.
Rifampin (Rifadin, Rimactane):
Rifampin (Rifadin, Rimactane) is an antibiotic drug used for the treatment of tuberculosis. It works by killing the bacteria that causes TB. Rifampin can take up to 8 weeks of daily doses to start working and may have serious side effects.
Application Insights:
The application segment includes active TB and latent TB. In 2017, the active TB segment dominated the market with a share of over 80% in terms of revenue. The high prevalence of HIV infection and rising number of reported cases due to multi-drug resistant tuberculosis are some factors responsible for the large share held by this segment.
The Latent TB program is expected to witness lucrative growth during the forecast period owing to increasing awareness about MDR-TB among healthcare professionals and patients as well as government initiatives such as ¢â‚¬Å“Stop Transmission¢â‚¬ programs in various countries including India, China, South Africa etc., which focus on early diagnosis & treatment for MDR-TB along with R&D activities being carried out by public & private institutions across the world.
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. The high prevalence of latent tuberculosis infection, increasing number of treatment-resistant cases, and rising government initiatives to increase the use of anti-TB drugs are some factors attributing towards its largest market share. Moreover, growing awareness about TB diagnosis and treatment among people is also expected to drive growth over the forecast period.
Asia Pacific is estimated to be fastest growing region during the forecast period owing to a rise in incidence rates coupled with an increase in prevalence across several Asian countries such as India & China & Indonesia & Malaysia etc., which has resulted into high demand for anti-TB drugs rendering this regional segment lucrative for global players operating within this industry vertical. In addition, favorable government initiatives promoting early diagnosis will further boost growth over coming years.
Growth Factors:
- Increasing incidence of tuberculosis (TB) across the globe
- Rising awareness about tuberculosis (TB) and its treatment options
- Growing demand for better and more effective TB treatments
- increasing funding for research and development of new TB drugs and therapies
- Technological advancements in the field of tuberculosis (TB) diagnosis and treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Tuberculosis (TB) Treatment Market Research Report
By Type
Isoniazid, Rifampin (Rifadin, Rimactane), Ethambutol (Myambutol), Pyrazinamide
By Application
Active TB, Latent TB
By Companies
Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd, Macleods Pharmaceutical Ltd, Dong-A ST Co., Ltd, Lupin Ltd, Janssen Products, LP, Mylan, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
147
Number of Tables & Figures
103
Customization Available
Yes, the report can be customized as per your need.
Global Tuberculosis (TB) Treatment Market Report Segments:
The global Tuberculosis (TB) Treatment market is segmented on the basis of:
Types
Isoniazid, Rifampin (Rifadin, Rimactane), Ethambutol (Myambutol), Pyrazinamide
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Active TB, Latent TB
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- Otsuka Pharmaceutical Co., Ltd
- Macleods Pharmaceutical Ltd
- Dong-A ST Co., Ltd
- Lupin Ltd
- Janssen Products, LP
- Mylan
- Sanofi
 Treatment Market Overview.svg)
Highlights of The Tuberculosis (TB) Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Isoniazid
- Rifampin (Rifadin, Rimactane)
- Ethambutol (Myambutol)
- Pyrazinamide
- By Application:
- Active TB
- Latent TB
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tuberculosis (TB) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Treatment Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
TB treatment is a combination of medications and/or surgery to clear the lungs of the TB bacteria.
Some of the major players in the tuberculosis (tb) treatment market are Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd, Macleods Pharmaceutical Ltd, Dong-A ST Co., Ltd, Lupin Ltd, Janssen Products, LP, Mylan, Sanofi.
The tuberculosis (tb) treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tuberculosis (TB) Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tuberculosis (TB) Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tuberculosis (TB) Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tuberculosis (TB) Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tuberculosis (TB) Treatment Market Size & Forecast, 2018-2028
4.5.1 Tuberculosis (TB) Treatment Market Size and Y-o-Y Growth
4.5.2 Tuberculosis (TB) Treatment Market Absolute $ Opportunity
Chapter 5 Global Tuberculosis (TB) Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Tuberculosis (TB) Treatment Market Size Forecast by Type
5.2.1 Isoniazid
5.2.2 Rifampin (Rifadin
5.2.3 Rimactane)
5.2.4 Ethambutol (Myambutol)
5.2.5 Pyrazinamide
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Tuberculosis (TB) Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Tuberculosis (TB) Treatment Market Size Forecast by Applications
6.2.1 Active TB
6.2.2 Latent TB
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tuberculosis (TB) Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tuberculosis (TB) Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Tuberculosis (TB) Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Tuberculosis (TB) Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Tuberculosis (TB) Treatment Market Size Forecast by Type
9.6.1 Isoniazid
9.6.2 Rifampin (Rifadin
9.6.3 Rimactane)
9.6.4 Ethambutol (Myambutol)
9.6.5 Pyrazinamide
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Tuberculosis (TB) Treatment Market Size Forecast by Applications
9.10.1 Active TB
9.10.2 Latent TB
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Tuberculosis (TB) Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Tuberculosis (TB) Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Tuberculosis (TB) Treatment Market Size Forecast by Type
10.6.1 Isoniazid
10.6.2 Rifampin (Rifadin
10.6.3 Rimactane)
10.6.4 Ethambutol (Myambutol)
10.6.5 Pyrazinamide
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Tuberculosis (TB) Treatment Market Size Forecast by Applications
10.10.1 Active TB
10.10.2 Latent TB
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Tuberculosis (TB) Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Tuberculosis (TB) Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Tuberculosis (TB) Treatment Market Size Forecast by Type
11.6.1 Isoniazid
11.6.2 Rifampin (Rifadin
11.6.3 Rimactane)
11.6.4 Ethambutol (Myambutol)
11.6.5 Pyrazinamide
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Tuberculosis (TB) Treatment Market Size Forecast by Applications
11.10.1 Active TB
11.10.2 Latent TB
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Tuberculosis (TB) Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Tuberculosis (TB) Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Tuberculosis (TB) Treatment Market Size Forecast by Type
12.6.1 Isoniazid
12.6.2 Rifampin (Rifadin
12.6.3 Rimactane)
12.6.4 Ethambutol (Myambutol)
12.6.5 Pyrazinamide
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Tuberculosis (TB) Treatment Market Size Forecast by Applications
12.10.1 Active TB
12.10.2 Latent TB
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Tuberculosis (TB) Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Tuberculosis (TB) Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Tuberculosis (TB) Treatment Market Size Forecast by Type
13.6.1 Isoniazid
13.6.2 Rifampin (Rifadin
13.6.3 Rimactane)
13.6.4 Ethambutol (Myambutol)
13.6.5 Pyrazinamide
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Tuberculosis (TB) Treatment Market Size Forecast by Applications
13.10.1 Active TB
13.10.2 Latent TB
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tuberculosis (TB) Treatment Market: Competitive Dashboard
14.2 Global Tuberculosis (TB) Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Johnson & Johnson
14.3.2 Otsuka Pharmaceutical Co., Ltd
14.3.3 Macleods Pharmaceutical Ltd
14.3.4 Dong-A ST Co., Ltd
14.3.5 Lupin Ltd
14.3.6 Janssen Products, LP
14.3.7 Mylan
14.3.8 Sanofi
